GS221

N/A

Report date: 2023/03/15 10:53:58
NME

Base Information

Drug NameGS221
Drug Alias NameGS-221GS221
ClassificationSmall molecules
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesGrand Pharmaceutical （China） Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGrand Pharmaceutical （China） Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A